AR-V7-a novel predictive and prognostic Biomarker Therapy Individualization in castration-resistant Prostate Cancer

被引：0
|
作者：
Oing, C. [1 ]
von Amsberg, G. [1 ]
Bokemeyer, C. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin Onkol Hamatol & Stammzelltransplantat Se, D-20246 Hamburg, Germany
来源：
ONKOLOGE | 2015年 / 21卷 / 09期
关键词：
ABIRATERONE ACETATE; ENZALUTAMIDE; DOCETAXEL;
D O I：
10.1007/s00761-015-3019-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：846 / 847
页数：2
相关论文
共 50 条
  • [1] AR-V7 – a novel predictive and prognostic biomarker: Individualized therapy for castration-resistant prostate cancer [AR-V7 – ein neuer prädiktiver und prognostischer Biomarker: Therapieindividualisierung beim kastrationsresistenten Prostatakarzinom]
    Oing C.
    von Amsberg G.
    Bokemeyer C.
    Der Onkologe, 2015, 21 (9): : 846 - 847
  • [2] AR-V7 splice variant detection and its value as prognostic biomarker in metastatic castration-resistant prostate cancer
    Guerra, A. J.
    Silva, E. Tavares
    Eliseu, M.
    Coucelo, M.
    Ferreira, A. M.
    Simoes, A. T.
    Parada, B.
    do Figueiredo, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [3] AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients
    Okegawa, Takatsugu
    Ninomiya, Naoki
    Masuda, Kazuki
    Nakamura, Yu
    Tambo, Mitsuhiro
    Nutahara, Kikuo
    PROSTATE, 2018, 78 (08): : 576 - 582
  • [4] Novel hormonal therapy for castration-resistant prostate cancer
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2012, 23 : 259 - 263
  • [5] The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
    Wang, Shuo
    Cao, Yudong
    Tang, Xingxing
    Yang, Xiao
    Ma, Jinchao
    Yu, Ziyi
    Yang, Yong
    Du, Peng
    JOURNAL OF MENS HEALTH, 2022, 18 (03)
  • [6] Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
    Katrin Schlack
    Konstantin Seitzer
    Neele Wüstmann
    Verena Humberg
    Norbert Grundmann
    Julie Steinestel
    Dorothee Tiedje
    Kambiz Rahbar
    Laura-Maria Krabbe
    Martin Bögemann
    Andres J. Schrader
    Christof Bernemann
    Scientific Reports, 12
  • [7] Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
    Schlack, Katrin
    Seitzer, Konstantin
    Wuestmann, Neele
    Humberg, Verena
    Grundmann, Norbert
    Steinestel, Julie
    Tiedje, Dorothee
    Rahbar, Kambiz
    Krabbe, Laura-Maria
    Boegemann, Martin
    Schrader, Andres J.
    Bernemann, Christof
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [8] Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer
    Aziz, Atiqullah
    Kempkensteffen, Carsten
    May, Matthias
    Lebentrau, Steffen
    Burger, Maximilian
    Chun, Felix K-H
    Brookman-May, Sabine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (06) : 649 - 666
  • [9] AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer
    To, Sarah Q.
    Kwan, Edmond
    Fettke, Heidi
    Mant, Andrew
    Docanto, Maria
    Martelotto, Luciano
    Bukczynska, Patricia
    Ng, Nicole
    Graham, Lisa-Jane
    Parente, Phillip
    Pezaro, Carmel
    Mahon, Kate
    Horvath, Lisa
    Todenhoefer, Tilman
    Azad, Arun
    CANCER RESEARCH, 2018, 78 (13)
  • [10] SUBCUTANEOUS FAT DISTRIBUTION IS A PROGNOSTIC BIOMARKER FOR MEN WITH CASTRATION-RESISTANT PROSTATE CANCER
    Lee, Jong Soo
    Park, Jee Soo
    Ha, Yoon Soo
    Lee, Kwang Suk
    Ahn, Hyun Kyu
    Ha, Jee Soo
    Kim, Do Kyung
    Lee, Dong Hoon
    Rha, Koon Ho
    Hong, Sung Joon
    Chung, Byung Ha
    Koo, Kyo Chul
    JOURNAL OF UROLOGY, 2018, 199 (04): : E849 - E849
12345